![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Effectiveness of 8-week glecaprevir/pibrentasvir(G/P) for treatment
naïve, non-cirrhotic patients with HCV infection in the TRIO Health network
|
|
|
Poster pdf attached to view tables better
Download the PDF
Reported by Jules Levin
AASLD 2018 San Francisco Nov 9-13
STEVEN L. FLAMM1, JENSKORT2, STEVEMARX2, JOHN STREZEWSKI2, BRUCEBACON3, MICHAEL P. CURRY4, NAOKYTSAI5, NICOLE WICK6, ZOBAIR YOUNOSSI7AND NEZAM AFDHAL4
1Northwestern University Feinberg School of Medicine, Chicago Illinois, USA;2AbbVie; 3Saint Louis University School of Medicine, St. Louis, Missouri, USA;4Beth Israel Deaconess Medical Center, Boston Massachusetts, USA; 5University of Hawaii, Honolulu, Hawaii, USA;6Trio Health Analytics, La Jolla, California, USA; 7Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, Virginia, USA
![1116181](../images%20/111618/111618-13/1116181.gif)
![1116182](../images%20/111618/111618-13/1116182.gif)
![1116183](../images%20/111618/111618-13/1116183.gif)
![1116184](../images%20/111618/111618-13/1116184.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|